Currently, numerous clinical trials for HER2-positive CRC are underway, and a variety of treatment strategies are being developed, including combinations of anti-HER2 antibodies, anti-HER2 antibodies and TKIs, ADCs, and anti-HER2 drugs and immune checkpoint inhibitors (ICIs) (Table 3 and Table 4). Here, ERBB2 is linked to colorectal carcinoma.